Characteristics of selected second-generation antiepileptic drugs used in dogs

• Autorzy: Ziolkowski H. , Jaroszewski J. J. , Ziolkowska N. , Jasiecka A.
• Języki publikacji: EN

Abstrakty

EN

A significant number of cases of clinical canine epilepsy remain difficult to control in spite of the applied treatment. At the same time, the range of antiepileptic drugs is increasingly wide, which allows efficient treatment. In the present paper we describe the pharmacodynamics and pharmacokinetics of the newer antiepileptic drugs which were licensed after 1990 but are still not widely used in veterinary medicine. The pharmacokinetic profiles of six of these drugs were tested on dogs. The results of experimental studies suggest that second generation antiepileptic drugs may be applied in mono- as well as in poli- treatment of canine epilepsy because of the larger safety margin and more advantageous pharmacokinetic parameters. Knowledge of the drugs’ pharmacokinetics allows its proper clinical appliance, which, in turn, gives the chance to improve the efficiency of pharmacotherapy of canine epilepsy.

Słowa kluczowe

EN

second generation drug; antiepileptic drug; dog; veterinary medicine; pharmacokinetics

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2012
• Tom: 15
• Numer: 3
• Opis fizyczny: p.571-582,ref.

Twórcy

autor

Ziolkowski H.

• Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury, Oczapowskiego 13, 10-718 Olsztyn, Poland

autor

Jaroszewski J. J.

autor

Ziolkowska N.

autor

Jasiecka A.

Bibliografia

• Adusumalli VE, Gilchrist JR, Wichmann JK, Kucharczyk N, Sofia RD (1992) Pharmacokinetics of felbamate in pediatric and adult beagle dogs. Epilepsia 33: 955-960.
• Adusumalli VE, Yang JT, Wong KK, Kucharczyk N, Sofia RD (1991) Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metab Dispos 19: 1116-1125.
• Ambrósio AF, Silva AP, Malva JO, Soares-da-Silva P, Carvalho AP, Carvalho CM (2001) Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 61: 1271-1275.
• Baruzzi A, Albani F, Riva R (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35: S14-S19.
• Benedetti MS, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E (2004) Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34: 281-300.
• Benes J, Parada A, Figueiredo AA, Alves PC, Freitas AP, Learmonth DA, Cunha RA, Garrett J, Soares-da-Silva P (1999) Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f] azepine-5-carboxamide derivatives. J Med Chem 42: 2582-2587.
• Berendt M, Gram L (1999) Epilepsy and seizure classification in 63 dogs: a reappraisal of veterinary epilepsy terminology. J Vet Intern Med 13: 14-20.
• Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E (2002) Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 51: 31-71.
• Boothe DM, Perkins J (2008) Disposition and safety of zonisamide after intravenous and oral single dose and oral multiple dosing in normal hound dogs. J Vet Pharmacol Ther 31: 544-553.
• Bourgeois B, Leppik IE, Sackellares JC, Laxer K, Lesser R, Messenheimer JA, Kramer LD, Kamin M, Rosenberg A (1993) Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 43: 693-696.
• Brown SD, Wolf HH, Swinyard EA, Twyman RE, White HS (1993) The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 34: S122-S123.
• Caldwell GW, Wu WN, Masucci JA, Mckown LA, Gauthier D, Jones WJ, Leo GC, Maryanoff BE (2005) Metabolism and exretion of the antiepileptic/antimigraine drug. Topiramate in animals and humans. Eur J Drug Metab Pharmacokinet 30: 151-164.
• Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I (2000) Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55: 236-242.
• Chronopoulos A, Stafstrom C, Thurber S, Hyde P, Mikati M, Holmes GL (1993) Neuroprotective effect of felbamate after kainic acid-induced status epilepticus. Epilepsia 34: 359-366.
• Degen PH, Flesch G, Cardot JM, Czendlik C, Dieterle W (1994) The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharm Drug Dispos 15: 519-526.
• DeLorenzo RJ, Sombati S, Coulter DA (2000) Effects of topiramate on sustained repetitive firing and spontaneous recurrent seizure discharges in cultured hippocampal neurons. Epilepsia 41: S40-S44.
• De Sarro G, Ongini E, Bertorelli R, Aguglia U, De Sarro A (1994) Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol 262: 11-19.
• Dewey CW (2006) Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Pract 36: 1107-1127.
• Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ (1989) First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Clin Pharmacol 37: 69-74.
• Dodgson SJ, Shank RP, Maryanoff BE (2000) Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41: S35-S39.
• Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN (1999) Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucbL059) in the rat. Epilepsy Res 34: 161-168.
• Ebert U, Reissmu¨ller E, Lo¨scher W (2000) The new antiepileptic drugs lamotrigine and felbamate are effective in phenytoin-resistant kindled rats. Neuropharmacology 39: 1893-1903.
• Edmonds HL Jr, Jiang YD, Zhang PY, Shank RP (1996) Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci 59: PL 27-31.
• Fujiwara Y, Sato M, Otsuki S (1986) Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology 90: 332-335.
• Fukunaga K, Saito M, Muto M, Yoshioka R, Mishima K, Fujiwara M, Orito K (2009) Steady-state pharmacokinetics of zonisamide in plasma, whole blood, and erythrocytes in dogs. J Vet Pharmacol Ther 33: 103-106.
• Gardocki JF, Labinski LS, Brown GL, Maryanoff BE (1986) Anticonvulsant activity of McN-4853 (M) 2, 3:4, 5-bis-O-(L-methylethylidene)-β-D-fructopyranose sulfamate in mice and rats Epilepsia 27: 648-649.
• Gee NS, Brown JP, Dissanayake VU, Offord J, Thrulow R, Woodruff GN (1996) The novel anticonvulsant drug, gabapentin (neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 271: 5768-5776.
• Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41: S10-S16.
• Giorgi O, Carboni G, Frau V, Orlandi M, Valentini V, Feldman A, Corda MG (1996) Anticonvulsant effect of felbamate in the pentylenetetrazole kindling model of epilepsy in the rat. Naunyn Schmiedebergs Arch Pharmacol 354: 173-178.
• Goa KL, Sorkin EM (1993) Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 46: 409-427.
• Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E (1993) ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222: 193-203.
• Guerreiro MM, Vigonius U, Pohlmann H, de Manreza ML, Fejerman N, Antoniuk SA, Moore A (1997) A double-blind, controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27: 205-213.
• Harty TP, Rogawski MA (2000) Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 39: 47-55.
• Hashimoto Y, Araki H, Futagami K, Kawasaki H, Gomita Y (2003) Effects of valproate, phenytoin, and zonisamide on clonic and tonic seizures induced by acute and repeated exposure of mice to flurothyl. Physiol Behav 78: 465-469.
• Henry TR, Leppik IE, Gumnit RJ, Jacobs M (1988) Progressive myoclonus epilepsy treated with zonisamide. Neurology 38: 928-931.
• Isbell H, Fraser HF (1950) Addiction to analgesics and barbiturates. J Pharmacol Exp Ther 99: 355-397.
• Isoherranen N, Yagen B, Soback S, Roeder M, Schurig V, Bialer M (2001) Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 42: 825-830.
• Jung H, Noguez A, Mayet L, Fuentes I, Gonzhlez-Esquivel DF (1997) The distribution of 10-hydroxy carbazepine in blood compartments. Biopharm Drug Dispos 18: 17-23.
• Kanba S, Yagi G, Komijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N, Asai M (1994) The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 18: 707-715.
• Kelly KM (1998) Gabapentin: Antiepileptic mechanism of action. Neuropsychobiology 38: 139-144.
• Klitgaard H, Matagne A, Gobert J, Wulfert E (1998) Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 353: 191-206.
• Kukanich B, Cohen RL (2011) Pharmacokinetics of oral gabapentin in greyhound dogs. Vet J 187: 133-135.
• Longo LP, Johnson B (2000) Addiction: Part I. Benzodiazepines-side effects, abuse risk, and alternatives. Am Fam Physician 61: 2121-2128.
• Loprinzi L, Barton DL, Sloan JA, Zahasky KM, Smith DA, Pruthi S, Novotny PJ, Perez EA, Christensen BJ (2002) Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 77: 1159-1163.
• Löscher W, Hönack D (1993) Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232: 147-158.
• Löscher W, Hönack D, Rundfeldt C (1998) Antiepi-leptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284: 474-479.
• Lukyanetz EA, Shkryl VM, Kostyuk, PG (2002) Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43: 9-18.
• Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101: 9861-9866.
• Macdonald RL, Kelly KM (1995) Antiepileptic drug mechanisms of action. Epilepsia 36: S2-S12.
• Madeja M, Margineanu DG, Gorji A, Siep E, Boerrigter P, Klitgaard H, Speckmann EJ (2003) Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 45: 661-671.
• Magenta P, Arghetti S, Di Palma F, Jann S, Sterlicchio M, Bianconi C, Galimberti V, Osio M, Siciliano G, Cavallotti G, Sterzi R (2005) Oxcarbazepine is effective and safe in the treatment of neuropathic pain: pooled analysis of seven clinical studies. Neurol Sci 26: 218-226.
• Masuda Y, Karasawa T, Shiraishi Y, Hori M, Yoshida K, Shimizu M (1980) 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneimittelforschung 30: 477-483.
• Matsumoto K, Miyazaki H, Fujii T, Kagemoto A, Maeda T, Hashimoto M (1983) Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Arzneimittelforschung 33: 961-968.
• McLean MJ, Bukhari AA, Wamil AW (2000) Effects of topiramate on sodium-dependent action- potential firing by mouse spinal cord neurons in cell culture. Epilepsia 41: S21-S24.
• McLean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Fedmann KF (1994) Oxcarbazepine: mechanisms of action. Epilepsia 35: S5-S9.
• Mellick GA (1995) Hemifacial spasm: successful treatment with felbamate. J Pain Symptom Manage 10: 392-395.
• Mimaki T, Tanoue H, Matsunaga Y, Miyazaki H, Mino M (1994) Regional distribution of 14C-zonisamide in rat brain. Epilepsy Res 17: 223-226.
• Moore SA, Muñana KR, Papich MG, Nettifee-Osborne J (2010) Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. Am J Vet Res 71: 337-341.
• Mori A, Noda Y, Packer L (1998) The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 30: 153-158.
• Murata M, Horiuchi E, Kanazawa I (2001) Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res 41: 397-399.
• Nakamura J, Tamura S, Kanda T, Ishii A, Ishihara K, Serikawa T, Yamada J, Sasa M (1994) Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 254: 83-89.
• Nicholson B (2000) Gabapentin use in neuropathic pain syndromes. Acta Neurol Scand 101: 359-371.
• Niespodziany I, Klitgaard H, Margineanu DG (2001) Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices. Neurosci Lett 306: 5-8.
• Okada M, Hirano T, Kawata Y, Murakami T, Wada K, Mizuno K, Kondo T, Kaneko S (1999) Biphasic effects of zonisamide on serotoninergic system in rat hippocampus. Epilepsy Res 34: 187-197.
• Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, Fukushima Y (1995) Effects of zonisamide on -+-++-dopaminergic system. Epilepsy Res 22: 193-205.
• Orito K, Saito M, Fukunaga K, Matsuo E, Takikawa S, Muto M, Mishima K, Egashira N, Fujiwara M (2008) Pharmacokinetics of zonisamide and drug interaction with phenobarbital in dogs. J Vet Pharmacol Ther 31: 259-264.
• Owen AJ, Ijaz S, Miyashita H, Wishart T, Howlett W, Shuaib A (1997) Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res 770: 115-122.
• Patterson EE, Goel V, Cloyd JC, O’Brien TD, Fisher JE, Dunn AW, Leppik IE (2008) Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. J Vet Pharmacol Ther 31: 253-258.
• Podell M, Fenner WR, Powers JD (1995) Seizure classification in dogs from a nonreferral-based population. J Am Vet Med Assoc 206: 1721-1728.
• Pollack MH, Matthews J, Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155: 992-993.
• Radulovic LL, Turck D, von Hodenberg A, Vollmer KO, McNally WP, DeHart PD, Hanson BJ, Bockbrader HN, Chang T (1995) Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos 23: 441-448.
• Rhee YS, Park S, Lee TW, Park CW, Nam TY, Oh TO, Jeon JW, Han SB, Lee DS, Park ES (2008) In Vitro/in vivo relationship of gabapentin from a sustained-release tablet formulation: a pharmacokinetic study in the beagle dog. Arch Pharm Res 31: 911-917.
• Rho JM, Donevan SD, Rogawski MA (1997). Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 280: 1383-1391.
• Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen, G, Selak I, Matagne A, Klitgaard H (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136: 659-672.
• Ritter FJ, Leppik, IE Dreifuss FE, Santilli N, Homzie R, Dodson WE, Glauser TA, Sackellares JC, Olson L, Garafolo EA, Shields WD, French J, Sperling M, Kramer LD, Kamin M, Rosenberg A, Shumaker R, Perhach JL, Dix R (1993) Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 328: 29-33.,
• Rock DM, Macdonald RL, Taylor CP (1989) Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD810, CI 912), a novel anticonvulsant. Epilepsy Res 3: 138-143.
• Rogvi-Hansen B, Gram L (1995) Adverse effects of established and new antiepileptic drugs: an attempted comparsion. Pharmacol Ther 68: 425-434.
• Sachdeo RC, Reife RA, Lim P, Pledger G (1997) Topiramate monotherapy for partial onset seizures. Epilepsia 38: 294-300.
• Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Aasved-Hoyt K (1985) Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia 26: 206-211.
• Schicht S, Wigger D, Frey HH (1996) Pharmacokinetics of oxcarbazepine in the dog. J Vet Pharmacol Ther 19: 27-31.
• Schwartz-Porsche D, Loscher W, Frey HH (1985) Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 8: 113-119.
• Segelman FH, Kelton E, Terzi RM, Kucharczyk N, Sofia RD (1985) The comparative potency of phenobarbital and five 1,3-propanediol dicarbamates for hepatic cytochrome P450 induction in rats. Res Commun Chem Pathol Pharmacol 48: 467-470.
• Sills GJ (2006) The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol 6: 108-113.
• Sofia RD, Gordon R, Gels M, Diamantis W (1993) Effects of felbamate and other anticonvulsant drugs in two models of status epilepticus in the rat. Res Commun Chem Pathol Pharmacol 79: 335-341.
• Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G (1996) Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 277: 121-127.
• Stefani A, Pisani A, De Murtas M, Mercuri NB, Marciani MG, Calabresi P (1995) Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 36: 997-1002.
• Stevenson CM, Radulovic LL, Bockbrader HN, Fleisher D (1997) Contrasting nutrient effects on the plasma levels of an amino acid like antiepileptic agent from jejunal administration in dogs. J Pharm Sci 86: 953-957.
• Stewart BH, Kugler AR, Thompson PR, Bockbrader HN (1993) A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 10: 276-281.
• Stiff DD, Zemaitis MA (1990) Metabolism of the anticonvulsant agent zonisamide in the rat. Drug Metab Dispos 18: 888-894.
• Streeter AJ, Stahle PL, Holland ML, Pritchard JF, Takacs AR (1995) Pharmacokinetics and bioavailability of topiramate in the beagle dog. Drug Metab Dispos 23: 90-93.
• Suzuki S, Kawakami K, Nishimura S, Watanabe Y, Yagi K, Seino M, Miyamoto K (1992) Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 12: 21-27.
• Suzuki Y, Nagai T, Ono J, Imai K, Otani K, Tagawa T, Abe J, Shiomi M, Okada S (1997) Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 38: 1035-1038.
• Swinyard EA, Sofia RD, Kupferberg HJ (1986) Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 27: 27-34.
• Taglialatela M, Ongini E, Brown AM, Di Renzo G, Annunziato L (1996) Felbamate inhibits cloned voltage-dependent Na+channels from human and rat brain. Eur J Pharmacol 316: 373-377.
• Taverna S, Sancini G, Mantegazza M, Franceschetti S, Avanzini G (1999) Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 288: 960-968.
• Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L (1998) A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29: 233-249.
• Taylor LA, McQuade RD, Tice MA (1995) Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycine-stimulated increases in intracellular Ca2+concentration. Eur J Pharmacol 289: 229-233.
• Tecoma ES (1999) Oxcarbazepine. Epilepsia 40: S37-S46.
• Theisohn M, Heimann G (1982) Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol 22: 545-551.
• Thomas WB (2010) Idiopathic epilepsy in dogs and cats. Vet Clin North Am Small Anim Pract 40: 161-179.
• Uno H, Kurokawa M, Masuda Y, Nishimura H (1979) Studies on 3-substituted 1,2-benzisoxazole derivates. 6. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J Med Chem 22: 180-183.
• Uno H, Kurokawa M, Natsuka K, Yamato Y, Nishimura H (1972) Studies on 3-substituted 1,2-benzisoxazole derivatives. Chem Phrmacol Bull 24: 632-643.
• Vollmer KO, Von Hodenberg A, Kölle EU (1986) Pharmacokinetics and metabolism of gabapentin in rat, dog, and man. Arzneimittelforschung 36: 830-839.
• Volosov A, Sintov A, Bialer M (1999) Stereoselective pharmacokinetic analysis of the antiepileptic 10-hydroxycarbazepine in dogs. Ther Drug Monit 21: 219-223.
• Walker MC, Patsalos PN (1995) Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 67: 351-384.
• Wallis RA, Panizzon KL, Fairchild MD, Wasterlain CG (1992) Protective effects of felbamate against hypoxia in the rat hippocampal slice. Stroke 23: 547-551.
• Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA (2002) Gabapentin augmentation therapyin bipolar depression. Bipolar Disord 4: 296-301.
• Wasterlain CG, Adams LM, Hattori H, Schwartz PH (1992) Felbamate reduces hypoxic-ischaemic brain damage in vivo. Eur J Pharmacol 212: 275-278.
• Wasterlain CG, Adams LM, Schwartz PH, Hattori H, Sofia RD, Wichmann JK (1993) Posthypoxic treatment with felbamate is neuroprotective in a rat model of hypoxia-ischemia. Neurology 43: 2303-2310.
• Wauquier A, Zhou S (1996) Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 24: 73-77.
• White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (1997) Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 28: 167-179.
• White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (2000) Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41: S17-S20.
• White HS, Brown D, Skeen GA, Wolf HH, Twyman RE (1995) The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia 36: S39-S40.
• White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD (1992) A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 33: 564-572.
• Wlaź P, Löscher W (1997) Anticonvulsant activity of felbamate in amygdala kindling model of temporal lobe epilepsy in rats. Epilepsia 38: 1167-1172.
• Wu SP, Tsai JJ, Gean PW (1998) Frequency-dependent inhibition of neuronal activity by topiramate in rat hippocampal slices. Br J Pharmacol 125: 826-832.
• Xu T, Bajjalieh SM (2001) SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 3: 691-698.
• Yang JT, Adusumalli VE, Kucharczyk N, Sofia RD (1991) Felbamate metabolism in the rat, rabbit, and dog. Drug Metab Dispos 19: 1126-1134.
• Yang JT, Morris M, Wong KK, Kucharczyk N, Sofia RD (1992) Felbamate metabolism in pediatric and adult beagle dogs. Drug Metab Dispos 20: 84-88.
• Zhang X, Velumian AA, Jones OT, Carlen PL (2000) Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 41: S52-S60.
• Zona C, Barbarosie M, Kawasaki H, Avoli M (1996a) Effects induced by the anticonvulsant drug topiramate on voltage-gated sodium currents generated by cerebellar granule cells in tissue culture. Epilepsia 37: S24
• Zona C, Ciotti MT, Avoli M (1996b) Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 231: 123-126